Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Рибоциклиб в 1-й линии терапии гормоночувствительного рака молочной железы
Рибоциклиб в 1-й линии терапии гормоночувствительного рака молочной железы
Жукова Л.Г., Ганьшина И.П., Гордеева О.О., Лубенникова Е.В. Рибоциклиб в 1-й линии терапии гормоночувствительного рака молочной железы. Современная Онкология. 2018; 20 (2): 38–41.
DOI: 10.26442/1815-1434_2018.2.38-41
DOI: 10.26442/1815-1434_2018.2.38-41
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Рак молочной железы – наиболее распространенная опухолевая патология среди женщин во всем мире. Несмотря на достигнутые успехи в лечении этого заболевания, остается высокая потребность в новых терапевтических агентах. В этой статье представлен обзор доказательных данных, свидетельствующих о высокой активности нового ингибитора циклинзависимых киназ – рибоциклиба. Кроме того, приведены наблюдения из собственного клинического опыта, накопленного в ходе клинического исследования IIIb фазы COMPLEEMENT.
Ключевые слова: рак молочной железы, 1-я линия терапии, ингибиторы CDK4/6, рибоциклиб.
Key words: breast cancer, first line, CDK4/6 inhibitors, ribociclib.
Ключевые слова: рак молочной железы, 1-я линия терапии, ингибиторы CDK4/6, рибоциклиб.
________________________________________________
Key words: breast cancer, first line, CDK4/6 inhibitors, ribociclib.
Полный текст
Список литературы
1. Злокачественные новообразования в России в 2016 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В.Старинского, Г.В.Петровой. М.: МНИОИ им. П.А.Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2018. / Zlokachestvennye novoobrazovaniia v Rossii v 2016 godu (zabolevaemost' i smertnost'). Pod red. A.D. Kaprina, V.V.Starinskogo, G.V.Petrovoi. M.: MNIOI im. P.A.Gertsena – filial FGBU “NMITs radiologii” Minzdrava Rossii, 2018. [in Russian]
2. Anderson WF et al. Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat 2002; 76: 27–36.
3. Ignatov A et al. Patterns of breast cancer relapse in accordance to biological subtype. J Cancer Res Clin Oncol 2018 Apr 19.
4. Beaver JA et al. The BOLERO-2 trial: The addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer. Future Oncol 2012; 8: 651–7.
5. Di Leo A et al. Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2018; 19 (1): 87–100.
6. Finn R et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol 2015; 16 (1): 25–35.
7. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57–70.
8. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011; 144: 646–74.
9. Kollmann K et al. A kinase-independent function of CDK6 links the cell cycle to tumor angiogenesis. Cancer Cell 2013; 24: 167–81.
10. Casimiro MC et al. Cyclin D1 determines estrogen signaling in the mammary gland in vivo. Mol Endocrinol 2013; 27: 1415–28.
11. Hortobagyi G et al. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. N Engl J Med 2016; 375: 1738–48.
12. Hortobagyi G et al. Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib + letrozole in hormone receptor-positive (HR+), HER2-negative (HER2-), advanced breast cancer (ABC). J Clin Oncol 2017; 35 (15 Suppl.): 1038.
13. Tripathy D et al. 2017 San Antonio Breast Cancer Symposium. December 5–9, 2017. Abstract GS2-05.
14. Fasching P et al. Phase III study of ribociclib (LEE011) plus fulvestrant for the treatment of postmenopausal patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (aBC) who have received no or only one line of prior endocrine treatment (ET): MONALEESA-3. J Clin Oncol 2016; 34 (15 Suppl.).
15. https://clinicaltrials.gov/ct2/show/NCT02941926
2. Anderson WF et al. Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat 2002; 76: 27–36.
3. Ignatov A et al. Patterns of breast cancer relapse in accordance to biological subtype. J Cancer Res Clin Oncol 2018 Apr 19.
4. Beaver JA et al. The BOLERO-2 trial: The addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer. Future Oncol 2012; 8: 651–7.
5. Di Leo A et al. Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2018; 19 (1): 87–100.
6. Finn R et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol 2015; 16 (1): 25–35.
7. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57–70.
8. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011; 144: 646–74.
9. Kollmann K et al. A kinase-independent function of CDK6 links the cell cycle to tumor angiogenesis. Cancer Cell 2013; 24: 167–81.
10. Casimiro MC et al. Cyclin D1 determines estrogen signaling in the mammary gland in vivo. Mol Endocrinol 2013; 27: 1415–28.
11. Hortobagyi G et al. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. N Engl J Med 2016; 375: 1738–48.
12. Hortobagyi G et al. Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib + letrozole in hormone receptor-positive (HR+), HER2-negative (HER2-), advanced breast cancer (ABC). J Clin Oncol 2017; 35 (15 Suppl.): 1038.
13. Tripathy D et al. 2017 San Antonio Breast Cancer Symposium. December 5–9, 2017. Abstract GS2-05.
14. Fasching P et al. Phase III study of ribociclib (LEE011) plus fulvestrant for the treatment of postmenopausal patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (aBC) who have received no or only one line of prior endocrine treatment (ET): MONALEESA-3. J Clin Oncol 2016; 34 (15 Suppl.).
15. https://clinicaltrials.gov/ct2/show/NCT02941926
2. Anderson WF et al. Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat 2002; 76: 27–36.
3. Ignatov A et al. Patterns of breast cancer relapse in accordance to biological subtype. J Cancer Res Clin Oncol 2018 Apr 19.
4. Beaver JA et al. The BOLERO-2 trial: The addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer. Future Oncol 2012; 8: 651–7.
5. Di Leo A et al. Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2018; 19 (1): 87–100.
6. Finn R et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol 2015; 16 (1): 25–35.
7. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57–70.
8. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011; 144: 646–74.
9. Kollmann K et al. A kinase-independent function of CDK6 links the cell cycle to tumor angiogenesis. Cancer Cell 2013; 24: 167–81.
10. Casimiro MC et al. Cyclin D1 determines estrogen signaling in the mammary gland in vivo. Mol Endocrinol 2013; 27: 1415–28.
11. Hortobagyi G et al. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. N Engl J Med 2016; 375: 1738–48.
12. Hortobagyi G et al. Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib + letrozole in hormone receptor-positive (HR+), HER2-negative (HER2-), advanced breast cancer (ABC). J Clin Oncol 2017; 35 (15 Suppl.): 1038.
13. Tripathy D et al. 2017 San Antonio Breast Cancer Symposium. December 5–9, 2017. Abstract GS2-05.
14. Fasching P et al. Phase III study of ribociclib (LEE011) plus fulvestrant for the treatment of postmenopausal patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (aBC) who have received no or only one line of prior endocrine treatment (ET): MONALEESA-3. J Clin Oncol 2016; 34 (15 Suppl.).
15. https://clinicaltrials.gov/ct2/show/NCT02941926
________________________________________________
2. Anderson WF et al. Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat 2002; 76: 27–36.
3. Ignatov A et al. Patterns of breast cancer relapse in accordance to biological subtype. J Cancer Res Clin Oncol 2018 Apr 19.
4. Beaver JA et al. The BOLERO-2 trial: The addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer. Future Oncol 2012; 8: 651–7.
5. Di Leo A et al. Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2018; 19 (1): 87–100.
6. Finn R et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol 2015; 16 (1): 25–35.
7. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57–70.
8. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011; 144: 646–74.
9. Kollmann K et al. A kinase-independent function of CDK6 links the cell cycle to tumor angiogenesis. Cancer Cell 2013; 24: 167–81.
10. Casimiro MC et al. Cyclin D1 determines estrogen signaling in the mammary gland in vivo. Mol Endocrinol 2013; 27: 1415–28.
11. Hortobagyi G et al. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. N Engl J Med 2016; 375: 1738–48.
12. Hortobagyi G et al. Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib + letrozole in hormone receptor-positive (HR+), HER2-negative (HER2-), advanced breast cancer (ABC). J Clin Oncol 2017; 35 (15 Suppl.): 1038.
13. Tripathy D et al. 2017 San Antonio Breast Cancer Symposium. December 5–9, 2017. Abstract GS2-05.
14. Fasching P et al. Phase III study of ribociclib (LEE011) plus fulvestrant for the treatment of postmenopausal patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (aBC) who have received no or only one line of prior endocrine treatment (ET): MONALEESA-3. J Clin Oncol 2016; 34 (15 Suppl.).
15. https://clinicaltrials.gov/ct2/show/NCT02941926
Авторы
Л.Г.Жукова*1, И.П.Ганьшина2, О.О.Гордеева2, Е.В.Лубенникова2
1 ГБУЗ «Московский клинический научно-практический центр им. А.С.Логинова» Департамента здравоохранения г. Москвы. 111123, Россия, Москва, ш. Энтузиастов, д. 86
2 ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н.Блохина» Минздрава России. 115478, Россия, Москва, Каширское ш., д. 23
*zhukova.lyudmila@rambler.ru
1 A.S.Loginov Moscow Clinical Scientific Practical Center of the Department of Health of Moscow. 111123, Russian Federation, Moscow, sh. Entuziastov, d. 86
2 N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation. 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23
*zhukova.lyudmila@rambler.ru
1 ГБУЗ «Московский клинический научно-практический центр им. А.С.Логинова» Департамента здравоохранения г. Москвы. 111123, Россия, Москва, ш. Энтузиастов, д. 86
2 ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н.Блохина» Минздрава России. 115478, Россия, Москва, Каширское ш., д. 23
*zhukova.lyudmila@rambler.ru
________________________________________________
1 A.S.Loginov Moscow Clinical Scientific Practical Center of the Department of Health of Moscow. 111123, Russian Federation, Moscow, sh. Entuziastov, d. 86
2 N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation. 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23
*zhukova.lyudmila@rambler.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.